GENOR-B(06998) completed the recommended merger and renamed as "Yiteng Jiahe Pharmaceutical Group Limited".

GENOR-B(06998) announces that all prerequisites for the proposed merger have been met, and the completion of the proposed merger took effect at 9:00 am on December 30, 2025 (Hong Kong time) (the effective time of the merger). The board of directors is pleased to announce that the special resolution regarding the proposed change of the company's name has been approved by the shareholders at a special general meeting. The company's English name has been changed from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited," and the company's dual foreign language Chinese name has been changed from "Jiahe Sheng Wu Yao Ye (Ka Man) Kong Gu You Xian Gong Si" to "Yi Teng Jiahe Yi Yao Ji Tuan You Xian Gong Si," with both changes taking effect from 9:00 am on December 30, 2025 (Hong Kong time) (the effective time of the merger). According to the merger agreement, following the completion of the merger at 9:00 am on December 30, 2025 (Hong Kong time) (the effective time of the merger), all directors serving at that time (excluding Mr. Yu Xian and Mr. Chen Wen) have resigned from their positions. From the effective time of the merger, the company has appointed Mr. Ni Xin and Ms. Zhai Jing as executive directors; Dr. David Guowei Wang as a non-executive director; Dr. Xu Qing and Ms. Zheng Jingjing as independent non-executive directors, and reappointed Mr. Chen Wen as an independent non-executive director (all these directors are collectively referred to as the "New Directors"). Mr. Yu Xian will continue to serve as a non-executive director on the board.